Literature DB >> 24966597

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Gülsüm Özlem Elpek1.   

Abstract

There have been considerable recent advances towards a better understanding of the complex cellular and molecular network underlying liver fibrogenesis. Recent data indicate that the termination of fibrogenic processes and the restoration of deficient fibrolytic pathways may allow the reversal of advanced fibrosis and even cirrhosis. Therefore, efforts have been made to better clarify the cellular and molecular mechanisms that are involved in liver fibrosis. Activation of hepatic stellate cells (HSCs) remains a central event in fibrosis, complemented by other sources of matrix-producing cells, including portal fibroblasts, fibrocytes and bone marrow-derived myofibroblasts. These cells converge in a complex interaction with neighboring cells to provoke scarring in response to persistent injury. Defining the interaction of different cell types, revealing the effects of cytokines on these cells and characterizing the regulatory mechanisms that control gene expression in activated HSCs will enable the discovery of new therapeutic targets. Moreover, the characterization of different pathways associated with different etiologies aid in the development of disease-specific therapies. This article outlines recent advances regarding the cellular and molecular mechanisms involved in liver fibrosis that may be translated into future therapies. The pathogenesis of liver fibrosis associated with alcoholic liver disease, non-alcoholic fatty liver disease and viral hepatitis are also discussed to emphasize the various mechanisms involved in liver fibrosis.

Entities:  

Keywords:  Cirrhosis; Extracellular matrix; Fibrogenesis; Hepatic stellate cells; Liver; Liver fibrosis; Myofibroblast

Mesh:

Substances:

Year:  2014        PMID: 24966597      PMCID: PMC4064072          DOI: 10.3748/wjg.v20.i23.7260

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  228 in total

Review 1.  The extracellular matrix: an active or passive player in fibrosis?

Authors:  Thomas N Wight; Susan Potter-Perigo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-04-21       Impact factor: 4.052

2.  The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes.

Authors:  Karlin Raja Karlmark; Henning W Zimmermann; Christoph Roderburg; Nikolaus Gassler; Hermann E Wasmuth; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 3.  Endothelin and hepatic wound healing.

Authors:  Al-karim Khimji; Don C Rockey
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

4.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

5.  Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice.

Authors:  Claudia Mitchell; Dominique Couton; Jean-Pierre Couty; Marie Anson; Anne-Marie Crain; Vinciane Bizet; Laurent Rénia; Stanislas Pol; Vincent Mallet; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

6.  Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis.

Authors:  Won-Il Jeong; Ogyi Park; Bin Gao
Journal:  Gastroenterology       Date:  2007-09-29       Impact factor: 22.682

7.  Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells.

Authors:  G Svegliati-Baroni; S Saccomanno; H van Goor; P Jansen; A Benedetti; H Moshage
Journal:  Liver       Date:  2001-02

8.  Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver.

Authors:  Andrew P Holt; Emma L Haughton; Patricia F Lalor; Andrew Filer; Christopher D Buckley; David H Adams
Journal:  Gastroenterology       Date:  2008-10-15       Impact factor: 22.682

Review 9.  Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin.

Authors:  Lindsay T McDonald; Amanda C LaRue
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

10.  The CYP2E1 inhibitor DDC up-regulates MMP-1 expression in hepatic stellate cells via an ERK1/2- and Akt-dependent mechanism.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Youqing Xu; Jidong Jia; Hong You
Journal:  Biosci Rep       Date:  2013-06-05       Impact factor: 3.840

View more
  96 in total

1.  A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo.

Authors:  Tao Guo; Zu-Long Liu; Qiang Zhao; Zhi-Min Zhao; Cheng-Hai Liu
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

Review 2.  Purinergic signaling in hepatic disease.

Authors:  E Velázquez-Miranda; M Díaz-Muñoz; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2019-10-01       Impact factor: 3.765

3.  Yu Jin Pulvis inhibits carbon tetrachloride-induced liver fibrosis by blocking the MAPK and PI3K/Akt signaling pathways.

Authors:  Wei Wu; Haiyu Piao; Fushun Wu; Yong Han; Dongzhu An; Yanling Wu; Zhenhua Lin; Yingshi Piao; Jingchun Jin
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 4.  Neuropilins and liver.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

5.  Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT).

Authors:  Merve Özel; Mevlut Baskol; Hilal Akalın; Gulden Baskol
Journal:  Cell Biochem Biophys       Date:  2021-03-10       Impact factor: 2.194

6.  MAPK inhibitors modulate Smad2/3/4 complex cyto-nuclear translocation in myofibroblasts via Imp7/8 mediation.

Authors:  Yufeng Jiang; Chao Wu; Alex Boye; Jiajun Wu; Jiyu Wang; Xiaochuan Yang; Yan Yang
Journal:  Mol Cell Biochem       Date:  2015-05-13       Impact factor: 3.396

7.  Chinese herbal formula Fuzheng Huayu alleviates CCl4-induced liver fibrosis in rats: a transcriptomic and proteomic analysis.

Authors:  Shu Dong; Fei-Fei Cai; Qi-Long Chen; Ya-Nan Song; Yang Sun; Bin Wei; Xiao-Yan Li; Yi-Yang Hu; Ping Liu; Shi-Bing Su
Journal:  Acta Pharmacol Sin       Date:  2017-11-02       Impact factor: 6.150

Review 8.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

9.  Inhibition of IRF3 expression reduces TGF-β1-induced proliferation of hepatic stellate cells.

Authors:  Ming-ming Ni; Tao Xu; Ya-rui Wang; Ying-hua He; Qun Zhou; Cheng Huang; Xiao-ming Meng; Jun Li
Journal:  J Physiol Biochem       Date:  2015-11-26       Impact factor: 4.158

10.  Epithelial-mesenchymal transition in liver fibrosis.

Authors:  Ya-Lei Zhao; Rong-Tao Zhu; Yu-Ling Sun
Journal:  Biomed Rep       Date:  2016-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.